The Medicines Company advances thrombosis therapy
If the trials are successfully completed and cangrelor receives regulatory clearance, the company believes cangrelor will be the first intravenous platelet inhibitor to market that binds directly to
ReviR Therapeutics has received a rare paediatric disease designation (RPDD) from the US Food and Drug Administration (FDA) for RTX-117, its investigational oral small-molecule therapy for Charcot-Marie-Tooth disease (CMT).